## **Patents Portfolio**

"Apolipoprotein E Polymorphism and Treatment of Alzheimer's Disease", which patents or patent applications claim the priority and benefit of Canadian patent application 2,111,503, International Patent Application PCT/CA94/00681, British Provisional patent application 1770-119 GB and International Patent Application PCT/CA/95/00240.

Country	Status	Number
United States	Granted	5935781
United Sates divisional	Pending	09/342993
Canada	Granted	2188933
France	Pending	Not available
Great Britain	Pending	Not available
Germany	Pending	69531557.9-08
Finland	Pending	964284
Japan	Granted	3285585
Australia-1	Granted	693193
Australia-2	Granted	733237
New-Zealand-1	Granted	284412
New Zealand-2	Granted	500375
Singapore	Granted	34770

"Pharmacogenetic Methods in the Treatment of Nervous System Diseases", which patents or patent applications claim the priority and benefit of international patent application WO9827227 filed December 12, 1997 which application claims the priority and benefit of U.S. application number 1996000766975 filed December 12, 1996.

Country	Status	Number
United States-1	Granted	6022683
United States-2 divisional	Pending	09/500162
Australia	Granted	745073
Canada	Pending	2275504
Europe	Allowed	97953011.0
Japan	Pending	10-527507

"Method for Determining the Prognosis of a Patient with a Neurological Disease", which patents or patent applications claim the priority and benefit of international patent application WO98/27226 filed December 16, 1997 which application claims the priority and benefit of U.S. application number US 1996000766975 filed December 16, 1996.

Country	Status	Number
United States 1	Granted	6251587
United States-2	Pending Notice of Appeal	09/548540
Canada	Pending	2275404
Europe	Allowed	97953011.0

Updated on Nov 2013 Page #39

Director, Molecular Neurobiology Unit, Douglas Institute.

Associate Director, Centre for Studies on the Prevention of Alzheimer's disease

"Methods for Treating a Neurological Disease by Determining BCHE Genotype", which patents or patent applications claim the priority and benefit of international patent application WO 99/66072 filed June 16, 1999 which application claims the priority and benefit of U.S. application number US US1998000089406P (U.S. provisional 60/089,406) filed June 16, 1998.

Country	Status	Number
United States	Granted	6291175
Canada	Granted	2330829
Australia	Granted	45292/99
Germany	Granted	69929787
Japan	Granted	2000-554880
Europe	Granted	EP1088104

"Genotyping of the Paraoxonase 1 Gene for Prognosing, Diagnosing, and Treating a Disease", which patents or patent applications claim the priority and benefit of international patent application WO 01/07644 filed July 19, 2000, which application claims the priority and benefit of U.S. application number US US199900001145602P (U.S. provisional 60/145,602) filed July 26, 1999.

Country	Status	Number
United States	Granted	6,573,049
Europe	Granted	EP 1 208 233B1

"Methods for Increasing ApoE levels for the Treatment of Neurodegenerative Disease" which patent or patent application claims the priority (Sept. 24, 1998) and benefit of provisional application 09/160,462 filed on September 24, 1997.

Country	Status	Number
United States	Granted	6,274,603

" Method for detecting a neuropathology by measuring apolipoprotein D" which patent or patent application claims the priority and benefit of provisional application 09/087,769 filed on September 12, 1999. Co-inventors: Terisse L., Rassart E. and Poirier J.

Country	Status	Number
Canada	Granted	2,333,946
PCT	Pending	WO9963350

"Hydroxymethylglutaryl CoA reductase and Diagnosis and Prognostication of Dementia which patent or patent application claims the priority and benefit of provisional U.S. provisional application 2005/0069881 A1filed on March 31, 2005.

Country	Status	Number
United States	Pending	10/487.747

"Genetic Profile of the Markers Associated with Alzheimer's Disease" which patent or patent application claims the priority and benefit of provisional U.S. provisional application 61/108,170 filed on October 24, 2008 Inventors: BELOUCHI ABDELMAJID [CA]; RAELSON JOHN VERNER [CA]; POIRIER JUDES [CA]; PAQUIN BRUNO [CA]; KEBACHE SEM [CA]; DEBRUS SOPHIE [CA]; VAN EERDEWEGH PAUL [US]; CROTEAU PASCAL [CA]; SEGAL JONATHAN [IL]; LITTLE RANDALL DAVID [CA]; KEITH TIM [US] + (BELOUCHI, ABDELMAJID, ; RAELSON, JOHN VERNER, ; POIRIER, JUDES, ; PAQUIN, BRUNO, ; KEBACHE, SEM, ; DEBRUS, SOPHIE, ; VAN EERDEWEGH, PAUL, ; CROTEAU, PASCAL, ; SEGAL, JONATHAN, ; LITTLE, RANDALL DAVID, ; KEITH, TIM).

Country	Status	Number
PCT	Pending	WO2010048497 (A1)
United States	Pending	61 / 108170

Page #40

"Bisphosphonate Inhibitors that Modulate Intracellular Phospho-Tau Levels in Neurons" which patent or patent application claims the priority and benefit of provisional U.S. provisional application filed on Nov 29, 2011.

Inventors: Youla S. Tsantrizos, Judes Poirier, Joris De Schutter and Yih-Shyan Lin

Country	Status	Number
United States	Pending	ADN 05001770-472USPR

V. 1. 1. N. 2012